Can-Fite BioPharma Ltd (CANF) has released an update.
Can-Fite BioPharma Ltd. has announced the European Patent Office’s Notice of Allowance for CF602, a drug candidate for treating erectile dysfunction, particularly benefiting diabetics and patients unresponsive to current treatments like Viagra. CF602 has demonstrated promising pre-clinical results, improving erectile function and vascular health in diabetic rats. The company is positioning CF602 as a high-value candidate in the growing Erectile Dysfunction market, projected to reach $6.6 billion by 2030.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
